SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL GLP-1/FGF21 DUAL AGONIST HEC88473 IN TYPE 2 DIABETES PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1b/2a MULTIPLE-ASCENDING-DOSE STUDY
HEPATOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined